Cargando…

Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study

OBJECTIVES: This study examines the characteristics of studies that Health Canada uses to grant full marketing authorisation for products given a conditional approval between 1 January 1998 and 30 June 2017. DESIGN: Cohort study. DATA SOURCES: Journal articles listing drugs that fulfilled their cond...

Descripción completa

Detalles Bibliográficos
Autor principal:	Lexchin, Joel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Health Policy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931291/ https://www.ncbi.nlm.nih.gov/pubmed/29705760 http://dx.doi.org/10.1136/bmjopen-2017-020377

Ejemplares similares

Time to market for drugs approved in Canada between 2014 and 2018: an observational study
por: Lexchin, Joel
Publicado: (2021)

Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006–2021: a cross-sectional study
por: Xie, Jinping, et al.
Publicado: (2023)

Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis
por: Lexchin, Joel
Publicado: (2017)

Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study
por: Lexchin, Joel
Publicado: (2014)

Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study
por: Diep, Dion, et al.
Publicado: (2020)

National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study
por: Lexchin, Joel, et al.
Publicado: (2022)

How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009
por: Lexchin, Joel
Publicado: (2014)

Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study
por: Lexchin, Joel
Publicado: (2019)

Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis
por: Ivama-Brummell, Adriana M., et al.
Publicado: (2023)

Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval
por: Matsushita, Shunsuke, et al.
Publicado: (2021)

Information about confirmatory studies required for new drugs conditionally approved by Health Canada: A cross-sectional study
por: Lexchin, Joel
Publicado: (2022)

Evaluation of Health in Pregnancy grants in Scotland: a protocol for a natural experiment
por: Dundas, Ruth, et al.
Publicado: (2014)

Marketing before patenting: implications for price controls in Canada
por: Lexchin, Joel
Publicado: (2010)

Biases in grant proposal success rates, funding rates and award sizes affect the geographical distribution of funding for biomedical research
por: Wahls, Wayne P.
Publicado: (2016)

How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study
por: Lexchin, Joel
Publicado: (2016)

Time to Marketing of Generic Drugs After Patent Expiration in Canada
por: Lexchin, Joel
Publicado: (2021)

Observational Evidence of For-Profit Delivery and Inferior Nursing Home Care: When Is There Enough Evidence for Policy Change?
por: Ronald, Lisa A., et al.
Publicado: (2016)

Prediction of therapeutic value of new drugs approved by health Canada from 2011−2020: A cross-sectional study
por: Lexchin, Joel
Publicado: (2023)

Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
por: Vokinger, Kerstin N., et al.
Publicado: (2022)

Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs
por: Giannuzzi, Viviana, et al.
Publicado: (2017)

Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort study
por: Larochelle, Matthieu, et al.
Publicado: (2017)

Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022
por: Luo, Xingxian, et al.
Publicado: (2023)

Estimation of Value-Based Price for Five High-Technology Medical Devices Approved by a Regional Health Technology Assessment Committee in Italy
por: Messori, Andrea, et al.
Publicado: (2022)

Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017
por: Zhu, Xingyue, et al.
Publicado: (2022)

Successful childhood obesity management in primary care in Canada: what are the odds?
por: Kuhle, Stefan, et al.
Publicado: (2015)

E-cigarette marketing in UK stores: an observational audit and retailers’ views
por: Eadie, D, et al.
Publicado: (2015)

The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States
por: Gagnon, Marc-André, et al.
Publicado: (2008)

Policies supporting informal caregivers across Canada: a scoping review protocol
por: Khayatzadeh-Mahani, Akram, et al.
Publicado: (2018)

Gender and racialisation of pharmaceutical sector leaders in Canada: a cross-sectional study
por: Satgunanathan, Kasthuri, et al.
Publicado: (2023)

Comparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance
por: Milliken, Debbie, et al.
Publicado: (2015)

Canada has an opportunity to address antimicrobial resistance through COVID-19 recovery spending
por: Somanader, Deborah S., et al.
Publicado: (2022)

Health Canada’s use of expedited review pathways and therapeutic innovation, 1995–2016: cross-sectional analysis
por: Lexchin, Joel
Publicado: (2018)

Tracing artificial trans fat in popular foods in Europe: a market basket investigation
por: Stender, Steen, et al.
Publicado: (2014)

The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines
por: Cavaleri, Marco, et al.
Publicado: (2021)

An analysis of redactions in Canada’s Common Drug Review Clinical Review Reports and how they relate to the patients’ voice
por: Soprovich, Allison, et al.
Publicado: (2017)

Genomic cloud computing: legal and ethical points to consider
por: Dove, Edward S, et al.
Publicado: (2015)

Use of healthcare services during the COVID-19 pandemic in urban Ethiopia: evidence from retrospective health facility survey data
por: Shuka, Zemzem, et al.
Publicado: (2022)

Piecing together the Inuit food security policy puzzle in Nunatsiavut, Labrador (Canada): protocol for a scoping review
por: Bowers, Renee, et al.
Publicado: (2019)

Artificial trans fat in popular foods in 2012 and in 2014: a market basket investigation in six European countries
por: Stender, Steen, et al.
Publicado: (2016)

Labour market trajectories after part-time sickness absence: a nationwide cohort study from Finland
por: Hartikainen, Elli, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ltpkauuokj6kb9a8mhnulqurl9